News
Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, ...
Hosted on MSN3mon
Siemens Agrees to Buy Dotmatics for $5.1 Billion, Expanding AI Portfolio to Life Sciences - MSNSiemens has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development cycles and help make breakthroughs in the life ...
MUNICH, April 2, 2025 /PRNewswire/ -- Siemens AG announces that it has signed an agreement to acquire Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for $5.1 billion ...
Siemens AG has agreed to acquire Dotmatics for $5.1 billion as part of a push to provide more artificial intelligence software to life sciences companies. The German company announced the deal for ...
German industrial giant Siemens AG said today it will pay $5.1 billion to acquire the life sciences data startup Dotmatics in an effort to expand its artificial intelligence offerings.. The ...
Siemens has agreed to acquire Dotmatics, the developer of a data platform for scientific research, taking it into the life sciences market. Siemens plans to combine Dotmatics’ drug research and ...
Siemens AG announces that it has signed an agreement to acquire Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for $5.1 billion from Insight Partners. This ...
Siemens SIE-0.21%decrease; red down pointing triangle has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development ...
Siemens has agreed to acquire Dotmatics for $5.1 billion, a combination the companies said would use artificial intelligence to speed up development cycles and help make breakthroughs in the life ...
MUNICH, April 2, 2025 /PRNewswire/ -- Siemens AG announces that it has signed an agreement to acquire Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for $5.1 billion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results